In 908 Chinese patients with chronic hepatitis B, pradefovir was non-inferior to tenofovir disoproxil fumarate for HBV DNA <29 IU/mL at week 48 in both HBeAg-positive and HBeAg-negative patients; drug-related adverse events by week 96 were 58.6% vs 71.9%.
RCTn = 908
Gao et al. A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B